Company profile: Axxam
1.1 - Company Overview
Company description
- Provider of integrated drug discovery services from target validation to lead generation, including assay development, high-throughput screening and hit-to-lead profiling, with a focus on small-molecule drugs targeting inflammation. Offers RNA biology platforms, SARS-CoV-2 cell-based and biochemical assays, a 349k-compound AXXDiversity library, and the AXXSense platform for flavors, fragrances and taste modulation.
Products and services
- AXXDiversity Library: Axxam's large-scale compound repository of approximately 349,000 small molecules engineered for hit discovery and lead optimization, delivering diverse chemical scaffolds for screening purposes
- Integrated Drug Discovery: Axxam architects end-to-end services spanning target validation, assay development, high-throughput screening, and hit-to-lead profiling, enabling comprehensive drug discovery support across multiple therapeutic areas
- RNA Biology Platforms: Axxam develops research-grade RNA technologies for drug discovery, including gene expression analysis, RNA-targeting compound screening, and splicing modulation studies employing advanced molecular biology toolsets
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Axxam
TissueGene
HQ: United States
Website
- Description: Provider of regenerative biopharmaceutical therapies for orthopedic disorders, offering TG-C, an allogeneic cell and gene therapy designed to treat knee osteoarthritis by reducing pain, improving function, and slowing disease progression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TissueGene company profile →
Hain Lifescience
HQ: Germany
Website
- Description: Provider of in-vitro diagnostics as a manufacturer and distributor, located in Nehren.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hain Lifescience company profile →
GenoSpace
HQ: United States
Website
- Description: Provider of a precision medicine software platform that makes biomedical data useful and usable, enabling interpretation, analysis, reporting, and collaboration. Offers clinical trial matching using clinical-genomic data, EMR-to-EDC integration to transfer EMR data to clinical trial databases, and study feasibility and site selection tools evaluating enrollment potential and competing trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenoSpace company profile →
Agendia
HQ: The Netherlands
Website
- Description: Provider of molecular diagnostics and personalized treatment planning for breast cancer, offering MammaPrint (70-gene analysis to assess recurrence risk, results in 6 days or less) and BluePrint (80-gene analysis to determine molecular subtype, results in less than 6 days). Supports research via the FLEX study and trials including SWOG S2206, INSIGHT, and I-SPY2.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agendia company profile →
Amyris
HQ: United States
Website
- Description: Provider of biotech chemical products made via advanced sugarcane-derived fermentation. Portfolio includes Neossance Squalane for cosmetics and skincare moisturization and barrier repair; Artemisinic Acid used in antimalarial treatments; Biosilica from sugarcane ashes for cosmetics; Neossance Hemisqualane as a plant-based silicone alternative; Biofene renewable specialty chemical building block; RealSweet Reb M zero-calorie sweetener.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amyris company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Axxam
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Axxam
2.2 - Growth funds investing in similar companies to Axxam
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Axxam
4.2 - Public trading comparable groups for Axxam
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →